Cross-protective efficacy of engineering serotype A foot-and-mouth disease virus vaccine against the two pandemic strains in swine

详细信息    查看全文

• 作者：Haixue Zheng¹ ; ^{haixuezheng@163.com" class="auth_mail" title="E-mail the corresponding author} ; Kaiqi Lian¹ ; Fan Yang¹ ; Ye Jin¹ ; Zixiang Zhu ; Jianhong Guo ; Weijun Cao ; Huanan Liu ; Jijun He ; Keshan Zhang ; Dan Li ; Xiangtao Liu ; ^{xiangtaoliu@caas.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Foot-and-mouth disease virus ; ASIA topotype ; Engineering foot-and-mouth disease virus ; Protective efficacy
• 刊名：Vaccine
• 出版年：2015
• 出版时间：26 October 2015
• 年：2015
• 卷：33
• 期：43
• 页码：5772-5778
• 全文大小：419 K

文摘

Foot-and-mouth disease (FMD) is a highly contagious vesicular disease that affects domestic and wild cloven-hoofed animals worldwide. Recently, a series of outbreaks of type A FMDV occurred in Southeast Asian countries, China, the Russia Federation, Mongolia, Kazakhstan and South Korea. The FMD virus (A/GDMM/CHA/2013) from China's Guangdong province (2013) is representative of those responsible for the latest epidemic, and has low amino acid identity (93.9%) in VP1 protein with the epidemic strain A/WH/CHA/09 from Wuhan, China in 2009. Both of isolates belong to the Sea-97 genotype of ASIA topotype. Therefore, the application of a new vaccine strain with cross-protective efficacy is of fundamental importance to control the spread of the two described pandemic strains. A chimeric strain rA/P1-FMDV constructed by our lab previously through replacing the P1 gene in the vaccine strain O/CHA/99 with that from the epidemic stain A/WH/CHA/09, has been demonstrated to exhibit good growth characteristics in culture, and the rA/P1-FMDV inactivated vaccine can provide protection against epidemic strain A/WH/CHA/09 in cattle. However, it is still unclear whether the vaccine produces efficient protection against the new pandemic strain (A/GDMM/CHA/2013). Here, vaccine matching and pig 50% protective dose (PD₅₀) tests were performed to assess the vaccine potency. The vaccine matching test showed cross-reactivity of sera from full dose vaccine vaccinated pigs with A/WH/CHA/09 and A/GDMM/CHA/2013 isolates, with average r₁ values of 0.94 ± 0.12 and 0.68 ± 0.06 (r₁ ≥ 0.3), which indicates that the rA/P1-FMDV vaccine is likely to confer good cross-protection against the two isolates. When challenged with two pandemic isolates A/WH/CHA/09 and A/GDMM/CHA/2013 strain, the vaccine achieved 12.51 PD₅₀ and 10.05 PD₅₀ per dose (2.8 渭g), respectively. The results indicated that the rA/P1-FMDV inactivated vaccine could protect pigs against both A/WH/CHA/09 and A/GDMM/CHA/2013 pandemic isolates.